FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Q4 2024 Earnings Call Transcript March 26, 2025 Journey Medical Corporation beats earnings expectations. Reported EPS is $0.08, expectations were $-0.22. Operator: Ladies and gentlemen, thank you for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

1 Day 2487 -2.68% DJIA 1.65% S&P Mid Cap 400 2.40% Health Care/Life Sciences -0.59% ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

2024 reflects a $1.0 million milestone payment pursuant to Journey’s license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) that became payable to us upon Cutia receiving marketing ...